No information is available on the clinical use of ivosidenib during breastfeeding. Because ivosidenib is 92 to 96% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is about 93 hours and it might accumulate in the infant. The manufacturer recommends that breastfeeding be discontinued during ivosidenib therapy and for 1 month after the dose.
关于ivosidenib在母乳喂养期间的临床应用尚无可用信息。由于ivosidenib与血浆蛋白的结合率为92%至96%，其在乳汁中的含量可能较低。然而，它的半衰期约为93小时，可能会在婴儿体内蓄积。制造商建议在ivosidenib治疗期间及停药后1个月内停止母乳喂养。
